# vTv Therapeutics share price today (vTv Therapeutics Inc., VTVT)

> vTv Therapeutics Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. VTVT · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/vtvt

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $24.03 (−7.6% in a year)
- P/E: 160.1×, against its own history
- Revenue (Mar 2026): ₹0.0 B
- Profit (Mar 2026): ₹0.0 B

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the vTv Therapeutics share price today? vTv Therapeutics Inc.'s share price was $24.03 at the close on 4 November 2026. That is 27.9% below its average price over the last 200 trading days. In the last 52 weeks it traded between $24 and $41, and at that close it was at the low of that range. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 13 weeks running. Over the last 1 year the share price moved +41% while the S&P 500 moved +18%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 7 August 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does vTv Therapeutics pay? vTv Therapeutics Inc. pays no dividend. In the last 9 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is vTv Therapeutics on? vTv Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is vTv Therapeutics profitable? vTv Therapeutics Inc. earned ₹0.0 B of net profit in the Mar 2026 quarter. The full FY24 year was a loss of ₹0.02 B. That is 65.5% of the quarter's revenue. The same quarter a year earlier lost ₹0.003 B. 8 of the last 9 reported quarters were loss-making. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much revenue does vTv Therapeutics make, and is it growing? vTv Therapeutics Inc. reported ₹0.0 B of revenue in the Mar 2026 quarter. Over 3 years it has grown −36.7% a year on average. The last full year, FY24, came in at ₹0.0 B. FY24 revenue was ₹0.0 B, −49.6% on the year before. Recent pace: the last four quarters grew +0.0% on average, against −36.7% a year over the longer run, so this year is growing faster than its own long-run rate. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much of its sales does vTv Therapeutics keep? vTv Therapeutics Inc.'s sales have fallen to very little: FY24 revenue was ₹0.0 B, against ₹0.0 B in FY21. On sales that small an operating margin is not a useful reading, so this section is left out until sales recover. ## Is vTv Therapeutics' profit turning into cash? vTv Therapeutics Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY24 its operations used ₹0.0 B of cash, against ₹0.0 B of profit. After null of spending on assets, free cash was ₹0.0 B: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: it spends almost nothing on new assets, so the cash goes on running the business. The next section shows the spending figures. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## Where does vTv Therapeutics' cash go? vTv Therapeutics Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent ₹0.0 B on assets over the last 1 years. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: ₹0.0 B over the last 1 years. In short: almost nothing is being spent on new assets, so the cash goes on running the business. ## What is vTv Therapeutics' P/E ratio, and how does it compare with its own history? vTv Therapeutics Inc.'s P/E is 160.1×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the vTv Therapeutics business getting better or worse? vTv Therapeutics Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. Why it matters: with too little history, we say so rather than guess a direction. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does vTv Therapeutics earn on its capital? vTv Therapeutics Inc. earned a ROE of −129% in FY24. That is up from a low of −328% in FY22. Its return on capital used (ROIC) is left out: on sales this small it reads −14%, a number that says nothing useful about the business. ## Does vTv Therapeutics have too much debt? vTv Therapeutics Inc. has total debt of ₹0.0 B against shareholder equity of ₹0.1 B as of Sep 2025, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from 0.06 in FY21 to 0.01 in FY24. So the returns on this page come from the business, not from borrowed money. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is the vTv Therapeutics shareholding pattern? 6.6% of vTv Therapeutics Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 3.9 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is vTv Therapeutics from balance-sheet trouble? For vTv Therapeutics Inc., the Z-score is 18.43. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 18.43 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does vTv Therapeutics rank in its industry? There is no score against its industry: vTv Therapeutics Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is vTv Therapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to vTv Therapeutics in size? vTv Therapeutics is the 173rd largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Arcturus Therapeutics Holdings Inc., ARS Pharmaceuticals, Inc. and Century Therapeutics, Inc. Just below it: Ocugen, Inc., SAB Biotherapeutics, Inc. and Fulcrum Therapeutics, Inc. ### Biotechnology companies close in size

1. [Arcturus Therapeutics Holdings Inc.](https://www.sectoralpha.in/us/stocks/arct) $309 million
2. [ARS Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/spry) $303 million
3. [Century Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/ipsc) $302 million
4. vTv Therapeutics Inc. $299 million
5. [Ocugen, Inc.](https://www.sectoralpha.in/us/stocks/ocgn) $297 million
6. [SAB Biotherapeutics, Inc.](https://www.sectoralpha.in/us/stocks/sabs) $289 million
7. [Fulcrum Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/fulc) $288 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Ur-Energy Inc.](https://www.sectoralpha.in/us/stocks/urg) $293 million · Uranium
2. [Envela Corporation](https://www.sectoralpha.in/us/stocks/ela) $293 million · Luxury Goods
3. vTv Therapeutics Inc. $293 million
4. [TrueBlue, Inc.](https://www.sectoralpha.in/us/stocks/tbi) $292 million · Staffing & Employment Services
5. [Seaport Entertainment Group Inc.](https://www.sectoralpha.in/us/stocks/seg) $292 million · Real Estate Services

## What else do people ask about vTv Therapeutics? ### What were vTv Therapeutics's latest quarterly results? vTv Therapeutics Inc. reported revenue of ₹0.0 B and net profit of ₹0.0 B for the Mar 2026 quarter. The operating margin was 63.1% (as of 4 November 2026). ### What is vTv Therapeutics's profit? vTv Therapeutics Inc. earned ₹0.0 B of net profit in the Mar 2026 quarter. Full-year FY24 profit was ₹0.0 B. The operating margin was 63.1% in the latest quarter (as of 4 November 2026). ### What is vTv Therapeutics's market cap? vTv Therapeutics Inc.'s market capitalisation is $299 M at a stock price of $24.03. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is vTv Therapeutics performing? vTv Therapeutics Inc.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 13 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will vTv Therapeutics's stock price go up? This page does not forecast vTv Therapeutics Inc.'s stock price. What it shows instead: the stock price is $24.03. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### What could break the vTv Therapeutics story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is vTv Therapeutics a stock worth studying right now? What the numbers show: vTv Therapeutics Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.